Ohcanbohtosat - Tebbutt, Niall C

Aiddostahte ozu
  1. 1
    Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature

    Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature Dahkki Chan, David L., Pavlakis, Nick, Shapiro, Jeremy, Price, Timothy J., Karapetis, Christos S., Tebbutt, Niall C., Segelov, Eva

    Almmustuhtton 2015
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature

    Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature Dahkki Chan, David L., Pavlakis, Nick, Shapiro, Jeremy, Price, Timothy J., Karapetis, Christos S., Tebbutt, Niall C., Segelov, Eva

    Almmustuhtton 2015
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials

    Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials Dahkki Hurwitz, Herbert I., Tebbutt, Niall C., Kabbinavar, Fairooz, Giantonio, Bruce J., Guan, Zhong-Zhen, Mitchell, Lada, Waterkamp, Daniel, Tabernero, Josep

    Almmustuhtton 2013
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus

    Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus Dahkki Davey, Rachel A, Tebbutt, Niall C, Favaloro, Jenny M, O'Neal, David N, Rae, Derek, Zajac, Jeffrey D, Best, James D

    Almmustuhtton 2006
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

    A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction Dahkki Shah, Manish A., Cho, Jae-Yong, Tan, Iain B., Tebbutt, Niall C., Yen, Chia-Jui, Kang, Alice, Shames, David S., Bu, Lilian, Kang, Yoon-Koo

    Almmustuhtton 2016
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines

    K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines Dahkki Yeung, Yvonne, Lau, David K., Chionh, Fiona, Tran, Hoanh, Tse, Janson W. T., Weickhardt, Andrew J., Nikfarjam, Mehrdad, Scott, Andrew M., Tebbutt, Niall C., Mariadason, John M.

    Almmustuhtton 2017
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

    Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study Dahkki Lau, David K., Tay, Rebecca Y., Yeung, Yvonne H., Chionh, Fiona, Mooi, Jennifer, Murone, Carmel, Skrinos, Effie, Price, Timothy J., Mariadason, John M., Tebbutt, Niall C.

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab*

    Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab* Dahkki Price, Timothy J, Hardingham, Jennifer E, Lee, Chee K, Townsend, Amanda R, Wrin, Joseph W, Wilson, Kate, Weickhardt, Andrew, Simes, Robert J, Murone, Carmel, Tebbutt, Niall C

    Almmustuhtton 2013
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]

    The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT] Dahkki Clarke, Stephen John, Burge, Matthew, Feeney, Kynan, Gibbs, Peter, Jones, Kristian, Marx, Gavin, Molloy, Mark P., Price, Timothy, Reece, William H. H., Segelov, Eva, Tebbutt, Niall C.

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial

    Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial Dahkki Klein, Oliver, Kee, Damien, Nagrial, Adnan, Markman, Ben, Underhill, Craig, Michael, Michael, Jackett, Louise, Lum, Caroline, Behren, Andreas, Palmer, Jodie, Tebbutt, Niall C., Carlino, Matteo S., Cebon, Jonathan

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Glycoprotein A33 deficiency: a new mouse model of impaired intestinal epithelial barrier function and inflammatory disease

    Glycoprotein A33 deficiency: a new mouse model of impaired intestinal epithelial barrier function and inflammatory disease Dahkki Williams, Benjamin B., Tebbutt, Niall C., Buchert, Michael, Putoczki, Tracy L., Doggett, Karen, Bao, Shisan, Johnstone, Cameron N., Masson, Frederick, Hollande, Frederic, Burgess, Antony W., Scott, Andrew M., Ernst, Matthias, Heath, Joan K.

    Almmustuhtton 2015
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

    The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors Dahkki Rosen, Lee S, Lipton, Lara, Price, Timothy J, Belman, Neil D, Boccia, Ralph V, Hurwitz, Herbert I, Stephenson Jr, Joe J, Wirth, Lori J, McCoy, Sheryl, Hei, Yong-jiang, Hsu, Cheng-Pang, Tebbutt, Niall C

    Almmustuhtton 2013
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial

    Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial Dahkki Tebbutt, Niall C, Price, Timothy J, Ferraro, Danielle A, Wong, Nicole, Veillard, Anne-Sophie, Hall, Merryn, Sjoquist, Katrin M, Pavlakis, Nick, Strickland, Andrew, Varma, Suresh C, Cooray, Prasad, Young, Rosemary, Underhill, Craig, Shannon, Jennifer A, Ganju, Vinod, Gebski, Val

    Almmustuhtton 2016
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis

    DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis Dahkki Tögel, Lars, Nightingale, Rebecca, Wu, Rui, Chüeh, Anderly C., Al-Obaidi, Sheren, Luk, Ian, Dávalos-Salas, Mercedes, Chionh, Fiona, Murone, Carmel, Buchanan, Daniel D., Chatterton, Zac, Sieber, Oliver M., Arango, Diego, Tebbutt, Niall C., Williams, David, Dhillon, Amardeep S., Mariadason, John M.

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

    Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer Dahkki Cutsem, Eric Van, Eng, Cathy, Nowara, Elzbieta, Świeboda-Sadlej, Anna, Tebbutt, Niall C., Mitchell, Edith, Davidenko, Irina, Stephenson, Joe, Elez, Elena, Prenen, Hans, Deng, Hongjie, Tang, Rui, McCaffery, Ian, Oliner, Kelly S., Chen, Lisa, Gansert, Jennifer, Loh, Elwyn, Smethurst, Dominic, Tabernero, Josep

    Almmustuhtton 2014
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers

    Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers Dahkki Herbertson, Rebecca A., Tebbutt, Niall C., Lee, Fook-Thean, MacFarlane, David J., Chappell, Bridget, Micallef, Noel, Lee, Sze-Ting, Saunder, Timothy, Hopkins, Wendie, Smyth, Fiona E., Wyld, David K., Bellen, John, Sonnichsen, Daryl S., Brechbiel, Martin W., Murone, Carmel, Scott, Andrew M.

    Almmustuhtton 2009
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

    VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer Dahkki Chionh, Fiona, Gebski, Val, Al-Obaidi, Sheren J., Mooi, Jennifer K., Bruhn, Maressa A., Lee, Chee K., Chüeh, Anderly C., Williams, David S., Weickhardt, Andrew J., Wilson, Kate, Scott, Andrew M., Simes, John, Hardingham, Jennifer E., Price, Timothy J., Mariadason, John M., Tebbutt, Niall C.

    Almmustuhtton 2022
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    RHOA inactivation enhances Wnt signaling and promotes colorectal cancer

    RHOA inactivation enhances Wnt signaling and promotes colorectal cancer Dahkki Rodrigues, Paulo, Macaya, Irati, Bazzocco, Sarah, Mazzolini, Rocco, Andretta, Elena, Dopeso, Higinio, Mateo-Lozano, Silvia, Bilić, Josipa, Cartón-García, Fernando, Nieto, Rocio, Suárez-López, Lucia, Afonso, Elsa, Landolfi, Stefania, Hernandez-Losa, Javier, Kobayashi, Kazuto, Cajal, Santiago Ramón y, Tabernero, Josep, Tebbutt, Niall C., Mariadason, John M., Schwartz, Simo, Arango, Diego

    Almmustuhtton 2014
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

    Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, dou... Dahkki Catenacci, Daniel V T, Tebbutt, Niall C, Davidenko, Irina, Murad, André M, Al-Batran, Salah-Eddin, Ilson, David H, Tjulandin, Sergei, Gotovkin, Evengy, Karaszewska, Boguslawa, Bondarenko, Igor, Tejani, Mohamedtaki A, Udrea, Anghel A, Tehfe, Mustapha, De Vita, Ferdinando, Turkington, Cheryl, Tang, Rui, Ang, Agnes, Zhang, Yilong, Hoang, Tien, Sidhu, Roger, Cunningham, David

    Almmustuhtton 2017
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

    Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study Dahkki Ohtsu, Atsushi, Ajani, Jaffer A., Bai, Yu-Xian, Bang, Yung-Jue, Chung, Hyun-Cheol, Pan, Hong-Ming, Sahmoud, Tarek, Shen, Lin, Yeh, Kun-Huei, Chin, Keisho, Muro, Kei, Kim, Yeul Hong, Ferry, David, Tebbutt, Niall C., Al-Batran, Salah-Eddin, Smith, Heind, Costantini, Chiara, Rizvi, Syed, Lebwohl, David, Van Cutsem, Eric

    Almmustuhtton 2013
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: